Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996561 | 0.94 | IDO1 (0.48) | IDO1MEN1KMT2ASIGMAR1DRD2 | |
| SCHEMBL28816253 | 0.92 | SIGMAR1 (0.50) | IDO1MEN1KMT2ASIGMAR1L3MBTL1 | |
| SCHEMBL450596 | 0.87 | CA1 (0.44) | IDO1MEN1KMT2ASIGMAR1DRD2 | |
| SCHEMBL2918971 | 0.79 | IDO1 (0.55) | IDO1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL27583098 | 0.79 | IDO1 (0.55) | IDO1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL27373 | 0.79 | IDO1 (0.55) | IDO1SIGMAR1LMNADRD2DRD4 | |
| SCHEMBL90811 | 0.76 | IDO1 (0.61) | IDO1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL703560 | 0.76 | IDO1 (0.61) | IDO1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL22029814 | 0.75 | IDO1 (0.67) | IDO1MEN1KMT2ASIGMAR1LMNA | |
| SCHEMBL196951 | 0.75 | IDO1 (0.67) | IDO1MEN1KMT2ASIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104302644-A | Thiazolecarboxamide derivatives and methods of use thereof | NIHON NOHYAKU CO LTD | 2015-01-21 | — | — | CN | disclosed |
| WO-2013041482-A1 | SIDE CHAIN-FUNCTIONALIZED PEG | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2013-03-28 | — | — | WO | disclosed |
| EP-1569904-B1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2012-01-11 | — | — | EP | disclosed |
| EP-1569904-A4 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCE (CN) | 2008-04-16 | — | — | EP | disclosed |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | LU XIAN-PING | 2008-02-28 | — | — | US | disclosed |
| US-7268157-B2 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-09-11 | — | — | US | disclosed |
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
| US-6972294-B1 | Compounds, their preparation and use | NOVO NORDISK, A/S (DK) | 2005-12-06 | — | — | US | disclosed |
| EP-1569904-A1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | Shenzhen Chipscreen Biosciences Ltd. (CN) | 2005-09-07 | — | — | EP | disclosed |
| US-6214820-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | NOVO NORDISK A/S (DK) | 2001-04-10 | — | — | US | disclosed |
| WO-2000063209-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000063190-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023451-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023445-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023416-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | IDO1 3502/4885MEN1 4746/4885KMT2A 1053/4885 |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | IDO1 2957/4885MEN1 4749/4885KMT2A 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.